KRAS Mutation in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis: A Biomarker of Cancer Biology or a Byproduct of Patient Selection?

Patients with colorectal cancer have experienced remarkable progress in a range of surgical and oncologic management strategies over the past few years, with a corresponding improvement in survival. The KRAS mutation may be a biomarker of cancer biology and prognosis, but also reflects patient selection.